Want to see JP:2395 full AI Analyst Report?
Shin Nippon Biomedical Laboratories, Ltd. (2395) Stock Price & Analysis
2395 Stock Chart & Stats
- Day’s Range
- JPY 1,484.00 - JPY 1,554.00
- 52-Week Range
- JPY 1,067.00 - JPY 2,005.00
- Previous Close
- JPY 1,520.00
- Volume
- N/A
- Average Volume (3M)
- 228.63K
- Market Cap
- JPY 62.70B
- Enterprise Value
- JPY 71.79B
- Total Cash (Recent Filing)
- JPY 14.33B
- Total Debt (Recent Filing)
- JPY 37.58B
- Price to Earnings (P/E)
- 11.7
- Beta
- 0.82
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- Mar 30, 2027
- Dividend Yield
- 3.32%
Bulls Say, Bears Say
Bulls Say
Specialized Contract Research Model
The fee-for-service model addresses recurring outsourcing needs across pharmaceutical and biotechnology development. By supporting preclinical safety and evaluation work required before clinical trials, the company participates in an essential stage of the drug-development process.
Solid Underlying Profitability
Healthy gross and net margins indicate that the company retains meaningful earnings power from its research services despite recent normalization. Positive, sizeable net income provides an operating base that can support continued investment and customer delivery over coming quarters.
Growing Asset And Equity Base
Growth in equity and total assets indicates that the business has expanded its financial and operating base over time. This provides greater capacity to support laboratory activities and service growth, although the benefit is moderated by the simultaneous rise in debt.
Bears Say
Revenue And Margin Deterioration
The combination of declining revenue and lower margins signals weaker operating momentum after the stronger 2022–2024 period. If this normalization persists, it could reduce earnings growth, limit operating leverage, and make profitability more dependent on project mix and utilization.
Rising Leverage
Debt rising toward parity with equity reduces financial flexibility and increases the sensitivity of results to any further profitability pressure. Higher leverage can constrain capital allocation and leave less room to absorb weaker research demand or fund expansion internally.
Weak And Uneven Cash Conversion
Low operating cash flow relative to reported earnings and several years of negative free cash flow show that accounting profits have not consistently converted into discretionary cash. Uneven conversion can restrict self-funded investment and make liquidity more dependent on working-capital outcomes.
Shin Nippon Biomedical Laboratories, Ltd. News
Shin Nippon Biomedical Laboratories Lifts First-Half Earnings Forecast on Strong CRO Performance
Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) has shared an announcement. Shin Nippon Biomedical Laboratories has sharply raised its consolidated earnings forecast for the first half of the fiscal
SNBL Sets New Management Structure and Highlights FY3/27 Q1 CRO Strategy
Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) just unveiled an update. Shin Nippon Biomedical Laboratories, Ltd. outlined its new management structure and future strategic direction alongside reporting an overview
Shin Nippon Biomedical Laboratories Keeps Annual Dividend at ¥50 as CRO Business Hits Record Highs
Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) has shared an update. Shin Nippon Biomedical Laboratories has approved a year-end dividend of ¥30 per share from retained earnings for shareholders
SNBL backs U.S. launch build-out for migraine drug Atzumi after licensing talks stall
Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) has issued an announcement. Shin Nippon Biomedical Laboratories has outlined a new commercialization strategy for Atzumi, an intranasal dihydroergotamine therapy developed by
Shin Nippon Biomedical Laboratories Outlines FY2026 Results and Strategic Focus
Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) just unveiled an update. Shin Nippon Biomedical Laboratories presented materials for its consolidated financial results briefing for the fiscal year ended March
SNBL Posts Flat Revenue, Lower Profits but Stronger Balance Sheet and Cash Ahead of FY2027 Growth Push
An update from Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) is now available. Shin Nippon Biomedical Laboratories reported fiscal 2026 revenue of ¥32.5 billion, up slightly year on year,
SNBL Revamps Top Management to Drive Long-Term Growth
Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) just unveiled an announcement. Shin Nippon Biomedical Laboratories has announced a leadership reshuffle, appointing Hideyuki Hirama as Representative President while long-serving leader
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array of laboratory services, including regulatory-compliant good laboratory practice (GLP) inspections. These studies cover general and specialized toxicity assessments, detailed pathological examinations, pharmacokinetic (PK) and pharmacodynamic (PD) analysis for biopharmaceuticals, immunotoxicity testing, and antibody production. The company also conducts investigations into reproductive and developmental toxicity, pharmacological mechanisms, and efficacy, alongside providing various imaging services. Furthermore, the organization specializes in developing and validating analytical methodologies, analyzing biological specimens, and determining pharmacokinetic parameters. It also conducts studies on absorption, distribution, metabolism, and excretion (ADME), often utilizing radioisotope-labeled compounds. Beyond preclinical and analytical work, it extends its expertise to clinical trial support through site management organization (SMO) services and broader clinical contract research organization (CRO) support. Its translational research division focuses on advancing novel medical solutions, such as the development of nasal drug delivery systems, nucleic acid-based adjuvants, and regenerative medicine therapies. Established in 1957, Shin Nippon Biomedical Laboratories, Ltd. maintains its headquarters in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ryoichi Nagata
- Employees
- 1,680
- Website
- www.snbl.co.jp
- Address
- 2438 Miyanoura-cho, Kagoshima, 891-1394, JP
Shin Nippon Biomedical Laboratories, Ltd. (2395) Earnings & Revenues
2395 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
